Steven Horwitz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the 5-year results of the double-blind Phase III ECHELON-2 study (NCT01777152). This study is an active comparator trial comparing the efficacy and safety of brentuximab vedotin in combination with CHP (A+CHP) with the current standard-of-care, the CHOP regimen, for patients with CD30-positive peripheral T-cell lymphoma (PTCL). A total of 452 patients with previously untreated PTCL were randomized to A+CHP or CHOP for six or eight cycles. The results presented here indicate that at an extended follow-up time of 5-years, compared to CHOP, frontline treatment with A+CHP continues to provide significant improvements in progression-free survival (PFS) and overall survival (OS), as seen at 3-years follow-up. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.